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ABSTRACT 
 Causing at least 215,000 deaths in the U.S. annually- more than prostate cancer, 
breast cancer, and AIDS combined- and rising, sepsis is one of the most deadly medical 
conditions in America.  Sepsis pathophysiology, however, is still incompletely 
understood, making it difficult for physicians to diagnosis and treat effectively.  Given 
the time-sensitivity of treatment, researchers are now searching for new methods to 
identify sepsis early, developing more accurate prognostic markers, and developing new 
target therapeutic candidates.  One biological component of interest in this research is the 
platelet-derived microparticle (PMP), a heterogeneous vesicle derived from the cell 
membrane of platelets found circulating in blood plasma.  In theory, as platelets are 
destroyed in sepsis, PMP levels in plasma could increase and thus play an important 
physiological role in the cascading deregulation of the clotting mechanism characteristic 
of sepsis. Furthermore, because of these possible roles in sepsis, PMP concentration 
presents a parameter of possible prognostic value. Data collected and analyzed to date in 
the context of this thesis (79 of 182 sepsis patients), a correlation between PMP level and 
sepsis severity was observed, but in an opposite manner than expected.   Rather than 
increasing with sepsis severity, PMP levels actually seem to decrease as the disease 
progresses.  Additionally, PMP levels strongly parallel platelet count.  These observations 
suggest these two markers (platelet count and PMPs) might be two different measures of 
the same underlying physiologic process.  However, definite conclusions cannot be made 
until analysis of the remaining patients enrolled in this study has been completed. 
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CHAPTER 1 
SEPSIS 
 
1.1 Sepsis Overview 
In sepsis, an infectious insult leads to systemic inflammatory response syndrome 
(SIRS), an acute immune response resulting in inflammation of the entire body.  Sepsis 
has an extremely high mortality rate of approximately 30%, depending on the definition 
and cohort studied, and accounts for at least 215,000 deaths per year in the United States 
alone. Most deaths can be attributed to the over-response and deregulation of the immune 
system rather than to the initial infection itself.13   Given the close relationship and cross-
talk between the immune and coagulation systems, widespread activation of the 
coagulation system is common in sepsis and may serve not only as a pathophysiologic 
response but also a therapeutic target. 
 
1.2 Thrombosis in Sepsis 
During sepsis, clotting cascades stop functioning properly.  Many pro- and anti-
inflammatory cytokines are released from mononuclear and endothelial cells.14 
Thrombosis occurs in later stages. Plasminogen stimulation and antithrombin-III 
activation take place in the fibrinolytic system, depleting fibrinolytic and fibrinogen 
substances.14  Coagulation abnormalities may manifest in varying degrees of severity 
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from minor changes in coagulation processes to wide spread microvascular thrombosis 
and disseminated intravascular coagulation (DIC).  DIC, which simultaneously causes 
deleterious clotting and bleeding, results in increased platelet destruction.14  The 
simultaneous occurrence of aberrant coagulation in some organs and bleeding in others 
significantly complicates sepsis treatment, as therapeutic measures may help 
complications in some organs while exacerbating problems in others.  If DIC becomes 
severe, deep vein thrombosis in various organs will result in multiple organ dysfunction 
syndrome (MODS), the prevailing signature of death in sepsis cases.14    
 
1.3 Sepsis Diagnosis 
 One reason for the high mortality rate of sepsis is the difficulty of early diagnosis 
for critical care physicians.  Sepsis is generally diagnosed in patients with confirmed or 
presumed infection and two or more of the following criteria for SIRS:  (1) a body 
temperature greater than 38°C or less than 36°C; (2) a heart rate greater than 90 beats per 
minute; (3) tachypnea, manifested by a respiratory rate greater than 20 breaths per 
minute, or hyperventilation, as indicated by a PaCO2 of less than 32 mm Hg; and (4) an 
alteration in the white blood cell count, such as a count greater than 12,000/cu mm, a 
count less than 4,000/cu mm, or the presence of more than 10 percent immature 
neutrophils (“bands”).15  Furthermore, severe sepsis is defined as sepsis associated with 
organ dysfunction, hypoperfusion abnormality, or sepsis-induced hypotension. 
Hypoperfusion abnormalities include lactic acidosis, oliguria, and acute alteration of 
mental status.15   Characteristics like hypoperfusion and high blood lactate concentrations 
are indicative of organ dysfunction, as both imply low oxygen delivery to organ systems.  
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Critical care physicians often utilize the Sequential Organ Failure Assessment (SOFA) 
score, which is a simple and objective score allowing for calculation of both the number 
and the severity of organ dysfunction in six organ systems (respiratory, coagulatory, 
liver, cardiovascular, renal, and neurologic).16	  	  For	  the	  coagulatory	  system	  score,	  low	  levels	  of	  circulating	  platelets,	  also	  known	  as	  thrombocytopenia,	  corresponds	  to	  a	  high	  SOFA	  score,	  which	  indicates	  a	  higher	  likelihood	  of	  organ	  dysfunction.	  	  Once 
sepsis-induced abnormalities like hypotension can no longer be improved by infusing 
fluids, the patient’s condition may be diagnosed as septic shock.17  Since most sepsis-
related deaths are the result of DIC and subsequent MODS, improving current methods or 
finding novel ways of recognizing thrombocyte abnormalities and organ dysfunction 
earlier provide an important step in increasing successful sepsis treatment. 
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CHAPTER 2 
PLATELET-DERIVED MICROPARTICLES AND THEIR POSSIBLE 
ROLE IN SEPSIS 
 
2.1 Microparticle Overview 
Microparticles (MPs) are a heterogeneous population of extracellular vesicles, 
ranging from 50 to 1000 nm, that make up a ubiquitous component of most- if not all- 
multicellular organisms.  MPs are generally derived from the plasma membrane of 
eukaryotic cells, including thrombocytes, leukocytes, endothelial cells, erythrocytes, 
adipocytes, and various cells of the central nervous system.1  MPs may contain many 
different components of the parent cell from which they originate.   
 
2.2 Platelet-derived Microparticle Overview and Biochemistry 
Platelet-derived microparticles (PMPs) are generated from the plasma membrane 
of thrombocytes (platelets) upon platelet activation by various physiological agonists 
such as collagen, thrombin, the complement membrane attack complex C5b-9, 
lipopolysaccharide, immune complexes, and viruses.1-4   Apoptotic platelets also release 
PMP.5  PMP circulate freely in blood plasma, making up the most significant portion of 
circulating MPs. Depending on the parent cell from which they originate, PMPs may 
contain a wide variety of bioactive substances, membrane-anchored receptors and 
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adhesion molecules on their surface, allowing specific interaction and crosstalk with 
various target cells.  Important biological molecules found in PMP include specific 
membrane adhesion proteins like P-selectins and integrins, tissue factor (TF) and other 
functional effectors that can regulate a number of processes- aggregation, adhesion, 
molecule expression, cell proliferation, apoptosis, endothelial migration- cytokines, and 
growth factors.6  Of most interest to the current study, however, externalization of 
phosphatidylserine (PS), which occurs upon platelet activation and/or platelet apoptosis, 
provides an efficient platform for the assembly of blood coagulation enzymes such as 
thrombin via the thrombin activation complex. Thrombin converts fibrinogen to fibrin, 
culminating in the activation of the coagulation cascade.6 The presence of 
phosphatidylserine in PMPs has been shown to induce more thrombin generation than 
phosphatidylserine alone, suggesting that PMPs enhance the procoagulatory response.7 
The presence of these molecules give PMPs the potential to closely parallel platelets in 
immune and hemostatic function; however, their smaller size and significantly larger 
count in circulating blood plasma imply that they could have a much more significant 
effect than is currently recognized. 
 
2.3 Physiological Function 
The primary physiological role of platelets is to stop bleeding by coagulating at 
blood vessel breaks in a process called hemostasis.  The clotting mechanism occurs in 
three steps: adhesion to molecules outside the opening, activation of chemical messengers 
and receptors and a cellular conformational change, and aggregation of cells through 
receptor bridges.8  In some cases, deleterious clotting can be induced in healthy blood 
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vessels, which may lead to obstructed blood flow.  This type of aberrant coagulation is 
called thrombosis, and is responsible for clinical conditions such as myocardial infarction 
(heart attack) and cerebrovascular accidents (strokes). If blood flow is obstructed enough 
or is completely blocked, tissue damage may occur.  Severe tissue damage can result in 
the failure of entire organ systems and even death.  The broad importance of better 
understanding of thrombotic processes broadened the implications of this line of research. 
The analogous biochemical composition of PMPs suggests that PMP may also play a role 
in the coagulation cascade- both normal and aberrant- however, the degree of their effect 
is not well understood.   
 
2.4 PMP Protocols and Flow Cytometry 
 In order to study PMPs, they must first be isolated.  Due to their analogous 
biochemical composition, PMPs must specifically be separated from platelets for any 
accurate results to be possible.  To achieve this separation, researchers may exploit the 
difference in size between PMPs and platelets through a series of centrifugations.9  Once 
isolated the research on PMPs could go in a number of directions; however, for this 
study, quantification of PMPs is the next step.  Methods of MP quantification have been 
established using flow cytometry, and PMPs may be detected specifically by binding 
with fluorescent antibodies to platelet-specific cell markers.7, 9-11 Antibodies to specific 
cell markers are conjugated to phycobilproteins like phycoerythrin (PE) and 
allophycocyanin (APC) to achieve fluorescence. Furthermore, PMPs specifically 
expressing procoagulant activity may be quantified by also labeling them with 
fluorescently labeled Annexin V to detect phosphatidylserine exposure.7  
	   7	  
Phosphatidylserine exposure is helps in the identification of procoagulant PMPs because 
it only is expressed on the outer surface of the plasma membrane in activated or apoptotic 
platelets.6-7  In order to avoid false positive detection by the flow cytometer, an 
appropriate negative control is utilized.11  Following appropriate fluorescent labeling 
protocol, the flow cytometer can accurately detect PMP concentration in a sample.  Flow 
cytometry works by streaming cells individually through a laser and recording the 
different wavelengths of scattered light emitted by the cell (Figure 1.1).12  The 
fluorescent molecules of labeled PMPs are excited to a higher energy state by the laser, 
giving off distinct wavelengths of light as they return to their resting energy state.12  
Thus, by gating the flow cytometric data to wavelengths specific to the fluorescent 
platelet cell markers and Annexin V, the number of PMPs per unit of volume can be 
determined, yielding a PMP concentration for the sample. 
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Figure 1.1 Schematic of a Flow Cytometer
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2.5 Pathophysiological Role of Platelets in Sepsis 
Sepsis decreases circulating platelets’ hemostatic function, maintains adhesion 
molecule expression and secretion capability, and modulates growth factor production, 
suggesting that sepsis alters the hemostatic function of the platelets and increases 
vascular endothelial growth factor (VEGF) release in a thrombin-independent manner.18  
As platelets’ normal hemostatic function decreases, the number of circulating platelets 
also decreases as their breakdown and consumption rapidly increases.  In severe sepsis 
cases this may manifest as DIC, leading to MODS.  With platelets being increasingly 
broken down and consumed, it seems intuitive that severe sepsis could cause an increase 
in PMPs, which may exacerbate the deregulation of the coagulatory system, leading to a 
vicious cycle. 
 
2.6 Possible Prognostic Value of PMPs 
 As sepsis deregulates the coagulatory system, resulting in the increased break 
down of platelets by apoptosis and macrophage consumption, we believe that PMP 
concentration in blood plasma may increase as they are released from platelets.  This 
change in platelet to PMP ratio could have a significant effect on the clinical 
manifestation of the disease and therefore presents possible prognostic value for critical 
care physicians.  In order to test our hypothesis that sepsis causes an increase in PMP 
count and the idea of PMPs being a novel, useful parameter of diagnostic and therapeutic 
value in severe sepsis, we first quantified PMP concentrations in severe sepsis patients 
and compared them to the degree of disease severity and a number of other sepsis-related 
clinical factors, including adverse clinical outcomes and factors, including past medical 
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history and demographic characteristics that may predispose a patient to developing 
significant complications.  A significant association to any of these adverse clinical 
outcomes or patient death could suggest a novel target for future therapeutics, and 
associations to the other factors could reveal which patients are most at risk of developing 
complications related to sepsis-induced changes in PMP concentration.
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CHAPTER 3 
METHODS 
 
3.1 Study Design and Setting 
This is a secondary analysis of blood samples collected as part of a prospective, 
randomized clinical trial compared two resuscitation strategies for the early emergency 
department treatment of severe sepsis. The results of this study have presented published 
previously, and demonstrated non-inferiority of a lactate guided resuscitation strategy 
compared to central venous oxygen guided resuscitation.16  Patients admitted to the 
Emergency Department of Carolinas Medical Center with severe sepsis or septic shock 
were assessed for inclusion, which required that patients be older than 17 years with 
confirmed or presumed infection.  The criteria for exclusion from the study were 
pregnancy, any primary diagnosis other than sepsis, suspected requirement for immediate 
surgery within 6 hours of diagnosis, an absolute contraindication to chest or neck central 
venous catheterization, cardiopulmonary resuscitation, transfer from another institution 
with a sepsis-specific resuscitative therapy underway, and advanced directive orders that 
would restrict the study procedure. Additionally, patients were excluded from this 
secondary analysis if no samples were available for analysis. Using a 24-hour day, 7-day-
week method that was previously established for the routine clinical care of sepsis 
patients at each of the participating institutions, an alert was sent to inform clinical care 
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resources when patients were identified as candidates.  Each enrolled patient or the 
patient’s legally authorized next of kin provided written informed consent prior to 
collection of data.19 All consented to give blood for study and further use.  Patient plasma 
samples were processed via immediate centrifugation, aliquoted, and frozen at -80 °C, 
transferred to the Emergency Department lab at the University of Mississippi Medical 
Center on dry ice, and kept frozen until the time of analysis.  79 out of the 182 patients 
enrolled in the study have been analyzed so far.   
 
3.2 Definitions 
 For this study, patients were assessed for inclusion if they were older than 17 
years of age and fit the study’s definition for severe sepsis or septic shock.  This included 
confirmed or presumed infection, having 2 or more systemic inflammatory response 
criteria,20 and having hypoperfusion evidenced by either a systolic blood pressure lower 
than 90 mm Hg after a minimum of 20 mL/kg rapid volume challenge or a blood lactate 
concentration of at least 36 mg/dL (4 mmol/L).19  
 
3.3 Demographic and Clinical Factors 
Demographic characteristics, such as age and gender, and clinical factors, such as 
source of infection (pneumonia, UTI, surgical wound), past medical history (diabetes, 
liver disease, hypetension, CHF, malignancy, transplant), and clinical presentation 
(presence or absence of hypotension, lactate elevation), were obtained from patient files. 
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3.4 Methods of Isolation 
 Previously frozen patient plasma was thawed at room temperature and centrifuged 
at 13,000 g for 2 min.  Microparticles (MPs) were isolated by centrifuging the resulting 
supernatant at 20,000 g for 20 min at 4°C.  The resulting MP pellet was washed twice 
with PBS before being resuspended in 550 µL of PBS. 
 
3.5 Preparation For Quantification By Flow Cytometry 
 The isolated MPs were fluorescently stained with specific antibodies in order to 
quantify the PMP level of each patient’s plasma.  50 µL of suspended MPs were added to 
three test tubes that would have no antibodies, control antibodies, and a triple-positive 
mix of antibodies added, respectively, in order of flow cytometer acquisition.  Each 
patient was analyzed in triplicate to reduce error, yielding a total of nine test tubes per 
patient.  sFITC-Annexin V (Beckman Coulter, Brea, CA) was used to detect 
phosphatidylserine (PS), PE-anti-CD61 and APC-anti-CD41 (Beckman Coulter) were 
used as surface markers for platelet MPs.  Platelet micropraticles were identified as triple-
positive MPs (Annexin-V+/CD61+/CD41+).  MPs were incubated with 50 µL antibody 
solution in Annexin V Binding Buffer (FITC-Annexin V, 1 µL; PE-anti-CD61, 20 µL; 
APC-anti-CD41, 10 µL) for 30 minutes at room temperature, protected from light.  400 
µL of Annexin V-FITC binding buffer was then added and then incubated for 10 min at 
room temperature, protected from light.  100 µL of AccuCheck Beads (Life 
Technologies, Frederick, MD) were added and manually mixed thoroughly just before 
acquisition on the flow cytometer.  Identical samples were incubated with isotype control 
IgG antibodies in the same manner to test for false positives.  Single staining controls and 
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control IgG antibodies were used to check fluorescence compensation settings and to set 
up positive regions on the Gallios flow cytometer (Beckman Coulter).  
 
3.6 PMP Quantification By Flow Cytometry 
 MP analysis was performed using monodisperse fluorescent beads (Megamix, 
BioCytex, Marseille, France) of three diameters (0.5, 0.9, and 3µm). Forward and side 
scatter parameters were plotted on logarithmic scales to best cover a wide size range. The 
MP-gate was determined by the Megamix bead diameters with MPs being defined as 
particles < 1.0 µm in size.  A minimum of 10,000 microspheres were read and PMP 
concentrations were calculated in accordance with the numbers of counting beads using 
the equation provided by the manufacturer (Absolute Count (cells/µL)= (number of cells 
counted/total number of beads counted) x number of AccuCheck Counting Beads per 
µL).  The number of cells counted was determined by subtracting the number of false 
positives like in Figure 3.1 from the number of triple-positives in like Figure 3.2.  The 
total number of beads counted was taken from graphs produced by the flow cytometer 
like in Figure 3.3.  Since flow cytometry analysis of platelet microparticles was 
performed in triplicate, the average of the three calculated PMP concentrations was used 
for each patient. 
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Figure 3.1 Screenshot of False Positive Detection by Flow Cytometer 
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Figure 3.2 Screenshot of Triple-Positive MP Detection by Flow Cytometer 
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Figure 3.3 Screenshot of Accucheck Bead Detection by Flow Cytometer 
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3.7 Statistical Methods 
 Statistical tests were performed with the PMP concentrations of the 79 patients 
that were analyzed.  Despite log transformation, PMP distributions remained non-
parametric, and therefore two-sample Wilcoxan rank-sum (Mann-Whitney) tests were 
performed with PMP levels to test for statistically significant differences between 
patients meeting the primary of in-hospital death versus survival. Differences in PMP 
levels among a number of clinical factors including the source of infection (pneumonia, 
UTI, surgical wound), past medical history (diabetes, liver disease, chronic renal 
insufficiency, congestive heart failure, hypertension, malignancy, transplant), clinical 
presentation (lactate elevation, spontaneous bacterial peritonitis), and sex were similarly 
tested.  Linear regression was used to assess for statistically significant associations 
between PMP level and both age and platelet count.  A Kruskal-Wallis equality-of-
populations rank test was performed on the patients’ SOFA coagulation scores, a 
determination of how sick someone is to assess the association between PMPs and 
severity of illness as assessed by organ failure.  Mann-Whitney tests were then done with 
PMP based on the SOFA coagulation score of the patient to test further for statistically 
significant correlations to in-hospital death or survival. Logistic regression was used to 
see if both PMP and platelet counts were independent predictors of death.  All tests were 
two-sided, and p-values of < 0.05 were considered significant.
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CHAPTER 4 
RESULTS & DISCUSSION 
 
4.1 PMP Concentrations 
 So far, the average PMP concentrations for 79 of the 182 enrolled severe sepsis 
patients have been determined.  Seeing that the concentrations do not follow a normal 
distribution curve (Figure 4.1), the moments of the actual distribution were determined.  
Of note, log transformation did not lead to a normal distribution, so data were analyzed 
based on raw values without transformation and using non-parametric statistics. Data 
analysis revealed median, mean, standard deviation, skewness, and kurtosis values of 
761.0, 1250.1, 1516.1, 2.6, and 11.9, respectively.  63% of our PMP concentrations fall 
below the mean, and consequently 27% rest above it.  Outliers of 8059 and 8308 
PMPs/µL account for much of this skew.  The statistical density of PMP levels decreases 
appreciably with increasing concentration (Figure 4.1).  Comparing the determined PMP 
concentrations to each of the factors below will clarify the significance of this 
distribution. 
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Figure 4.1 Distribution of Observed PMP Concentrations  
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4.2 PMP Concentrations Compared to In-Hospital Death or Survival 
 One of the main goals of this research was to investigate if PMP count is 
associated with adverse clinical outcomes and patient death, as a significant association 
might suggest a novel target for future therapeutics.  In order to do so, a number of 
clinical factors were recorded for each sepsis patient and compared to the determined 
PMP concentrations.  Statistical tests were performed for each factor to establish if a 
significant correlation exists.  First, the patients’ PMP count was compared to the 
incidence of in-hospital death or survival at the time of plasma extraction.  Of the 79 
patients studied so far, 13 (16%) died, while 66 (84%) survived.  Figure 4.2 shows this 
data as a box and whisker graph, noting median, quartiles, and outlier PMP counts by 
death or survival.  A Mann-Whitney rank sum test gave a statistically significant p-value 
of 0.04 (Table 4.1).  Thus, higher levels of PMP in plasma were associated with patient 
survival, establishing a positive correlation between PMP level and survival. 
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Figure 4.2 PMP Concentrations Separated by In-Hospital Death or Survival 
*Death = 0; Survival = 1 
 
 
 
 
 
 
Table 4.1 Statistical Test for Correlation Between In-Hospital Death or Survival and 
PMP Concentration  
Two-sample Wilcoxon Rank-sum (Mann-Whitney) Test 
vsbin Observed Rank Sum Expected 0 13 365 520 
1 66 2795 2640 
combined 79 2795 3160 
  
P > |z| 0.0404 
	   23	  
4.3 The Association of PMPs with SOFA Coagulation Score and Platelet 
Count 
 Once a correlation had been established between PMP count and mortality, we 
wanted to expound on this idea further to see if PMP concentration could indicate not 
only the death or survival of the patient but also the specific degree of disease severity.  
In sepsis, critical care physicians utilize the SOFA scoring system to determine sepsis 
severity by quantifying dysfunction of organ systems.  For the coagulatory system, the 
degree of dysfunction is established by assessing platelet count (Table 4.2). A Kruskal-
Wallace equality-of-populations test was performed to determine if PMP concentration 
varies with circulating platelet level (Table 4.3).  With a P < .05 (Table 4.3), the results 
indicate that a relationship does exist between SOFA coagulatory score and PMPs and, 
thus, between platelet and PMP count.  However, contrary to expectations, PMP count, 
like platelet count, trended downward on average with increasing SOFA coagulation 
score (Table 4.3, Figure 4.3, Figure 4.4).  A logistic regression was performed with 
PMP and platelet counts to determine if these two measures represent independent 
predictors of death or whether they are co-linear, suggesting they may represent alternate 
measurements of the same underlying phenomenon (Table 4.4).  Analyzing the 79 
patients so far, these two factors do not appear to be independent predictors (Table 4.4), 
meaning they may be two different measures of the same underlying physiologic process.  
However, the p-value approaches statistical significance for independence, so further 
analysis of the remaining patients will be important to further investigate our hypotheses.  
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Table 4.2 SOFA Coagulation Scoring 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.3 Statistical Test for Determining If PMP Concentration Varies With Platelet 
Count 
 
 
 
 
Figure 4.3 PMP Concentrations Separated By SOFA Coagulatory Score 
SOFA Coagulation Score 
 0 1 2 3 4 
Platelet Count 
(x103/µL) 
≥150 <150 <100 <50 <20 
 
Kruskal-Wallis Equality-of-populations Rank Test 
SOFACoag Score Observed Rank Sum 
0 57 2546.00 
1 11 335.50 
2 6 135.50 
3 4 136.00 
4 1 7.00 
   
 P 0.0398 
Averag
e	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Figure 4.4 PMP Concentration vs. Platelet Count 
 
  
 
Table 4.4 Statistical Analysis of PMP Concentration and Platelet Count As Independent 
Predictors of Death  
Logistic Regression of PMP Average and Platelet Count 
 Odds Ratio Std. Err. z P > |z| [95% Conf. Interval] 
Average 1.0011 0.0005 2.01 0.044 1.0000   1.0022   
 Odds Ratio Std. Err. z P > |z| [95% Conf. Interval] 
Average 1.0008 0.0006 1.35 0.179 0.99964   1.0019 
Platelets 1.0072 0.0038 1.90 0.057 0.99977   1.0147 
 Odds Ratio Std. Err. z P > |z| [95% Conf. Interval] 
Platelets 1.0036 0.0015 2.46 0.014 1.0007   1.0065 
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4.4 PMP Concentrations Compared to Other Clinical Factors 
 Once the above correlations to death and disease severity had been established, as 
well as the relationship to platelet count, PMP concentrations were compared to a number 
of other clinical factors.  PMPs were analyzed by Mann-Whitney tests to determine if a 
relationship to the original source of infection that lead to each patients case of severe 
sepsis exists.  Three categories for the source of infection were analyzed: pneumonia, 
urinary tract infection (UTI), and surgical wound (Table 4.5).  The same tests were 
performed on seven past medical history factors:  diabetes, liver disease, chronic renal 
insufficiency (CRI), congestive heart failure (CHF), hypertension, malignancy, and 
transplant (Table 4.6).  Two clinical presentation factors were also evaluated:  lactate 
elevation and spontaneous bacterial peritonitis (SBP) (Table 4.7).  Lastly, the effects of 
sex and age on PMP level were considered (Table 4.8).  None of these factors were 
significantly associated with PMP level.  While we cannot definitely state there is no 
relationship between these factors and PMPs, given the moderate sample size we would 
expect any potential relationships to be relatively small with small effect sizes. 
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Source of Infection 
 Pneumonia UTI Surgical Wound 
P > |z| 0.9172 0.8927 0.9387 
 
Table 4.5 Mann-Whitney Tests for Correlation Between Source of Infection and PMP 
Concentration 
 
Past Medical History 
 Diabetes Liver 
Disease 
CRI CHF Hypertension Malignancy Transplant 
P > |z| 0.5952 0.3921 0.6620 0.9240 0.9413 0.0996 0.5610 
 
Table 4.6 Mann-Whitney Tests for Correlation Between Past Medical History and PMP 
Concentration 
 
Clinical Presentation 
 Lactate Elevation SBP 
P > |z| 0.5832 0.2401 
 
Table 4.7 Mann-Whitney Tests for Correlation Between Clinical Presentation and PMP 
Concentration 
 
Other Clinical Factors 
 Age Sex 
P > |z|* 0.537 0.7120 
 
Table 4.8 Statistical Tests for Correlation Between Age/Sex and PMP Concentration 
*Sex was analyzed by a Mann-Whitney test, while regression analysis was used for age. 
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4.5 Discussion 
 With only 79 of 182 enrolled patients having been analyzed, our results thus far 
represent only preliminary findings; however, the initial data does suggest a few 
interesting corollaries between PMPs and sepsis- in large part contrary to our initial 
hypothesis.  The statistical distribution of the data from our enrolled patients gave an 
initial indication that PMP concentrations tend to manifest mostly in lower levels in 
severe sepsis (Figure 4.1).  One of the main focuses of this study was to determine if 
PMP concentration could be a useful parameter of prognostic value in severe sepsis cases 
and if PMP count could be used to determine the likelihood of a patient’s outcome. In 
light of the remarkably high mortality rate of sepsis,13 the first issue that we examined 
was whether or not PMP levels in circulating blood plasma are indicative of in-hospital 
death or survival.  The statistical analysis of PMP counts separated by in-hospital death 
or survival revealed a significant correlation between PMP level and patient outcome.  
Nearly every enrolled patient who had died from severe sepsis complications had a PMP 
concentration less than 1500 PMPs per µL, while this number exhibited about an average 
concentration for living patients.  These data suggests that PMP is a significant predictor 
of survival and could serve as a prognostic marker. 
Since PMP levels, like platelet count16, were lower rather than higher in patients 
with a negative outcome, this trend- although significant- was contrary to the 
expectations of our hypothesis.  To test the parallel between PMP and platelet count 
further, we performed a statistical analysis on PMP counts separated by the patient’s 
SOFA coagulation score, a quantitative measure of sepsis severity, which is scored 
according to the patient’s platelet count.  Analysis once again showed a statistically 
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significant direct relationship, as PMPs seem to mirror platelets, decreasing with 
progressive disease severity.  It is possible, therefore, that having fewer platelets 
circulating decreases the chance of generating PMPs.  In order to determine if this 
parallel between PMPs and platelets occurs independent of each other, PMP 
concentration was then compared directly to platelet count with a logistic regression test.  
This analysis revealed that PMP and platelet count are not independent factors but instead 
seem to cancel each other out.  This suggests that the same underlying physiologic 
process can be attributed to these measures. Thus, while PMPs do represent a prognostic 
marker, the same data appears to be available via a common clinical, easy to perform test 
in platelet count. This suggests against the true clinical utility of PMPs as a prognostic 
marker. 
Although we knew that platelets and PMPs should share many physiologic 
functions, it was thought that the destruction of platelets in severe sepsis would result in 
the propagation of PMPs.  Assuming this preliminary data holds up when more patients 
are analyzed, the results raise some doubts toward the marginal prognostic value of PMP 
concentrations in severe sepsis patients for critical care physicians, as platelet counts are 
a much easier and cost efficient measure.  Despite having an outcome opposite to what 
we had theorized, the results raise novel questions to be answered by future research.  
Most notably, if completion of the remaining samples demonstrates that PMPs are an 
independent predictor of mortality after controlling for initial platelet count, it could be 
that after platelet count is considered, PMPs do contribute to mortality all other things 
being equal.  However, it is too early to draw any conclusions until completion of the 
remaining samples. 
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The exact physiologic mechanism affecting both PMP and platelet counts in 
severe sepsis can likely be attributed to the interaction of number of different processes.  
Previous research has attributed low platelet count in septic patients to overabundance of 
cytokines, endothelial damage, and the suppression of bone marrow.14  Since cytokine 
overabundance and endothelial damage should contribute to an increase in PMPs, bone 
marrow suppression may be occurring at a sufficient magnitude to outweigh those 
effects, yielding PMP and platelet counts that mirror each other as we have observed in 
our results; however, further research would be necessary to confirm this.   Also, these 
results still do not elucidate much about the role that PMPs play in sepsis but merely 
show that concentrations parallel those of platelets; so further inquiry could still be done.  
Specific pathophysiologic effects of PMPs in vivo were not investigated in the current 
study, but would be an area for future research as well.  Another important question 
involves PMPs and platelets’ close relationship to severe sepsis and the degree to which a 
septic patient’s natural platelet generation and composition predisposes them to 
descending into severe cases.   Research has already shown that sepsis induces alterations 
in platelets, leading to their cascading dysfunction;18 however, the underlying reasons 
causing one individual to be more susceptible than another to these deleterious effects of 
sepsis are not yet well understood.  Further research on PMPs will be necessary to 
determine if they play a role in these sepsis-specific effects on the coagulatory system.   
Apart from PMPs’ close relationship to platelets and patient outcome, our 
preliminary data demonstrated no other significant corollaries between PMP 
concentration and the other fourteen sepsis-related clinical factors that were considered. 
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Eliminating these possible confounding factors, this further indicates PMPs’ specific 
association to platelets in sepsis.   
Aside from the obvious issue of this initial data only representing roughly half of 
our total number of enrolled patients, a few other limitations of this study warrant 
discussion.  For one, the small size of MPs may affect the precision of flow cytometric 
analysis.21-23  We attempted to minimize these effects by appropriate gating and choosing 
of monodisperse beads, yet it remains possible that some particularly small PMPs were 
excluded.  Antibody aggregates may also be of concern23; however, our addition of false-
positive detection in our protocol should make their effects on our data minimal.11  
Additionally, the lack of variable standardization in flow cytometric quantification limits 
our data in terms of comparability to other similar studies.  These variables notably 
include the instruments and the fluorescently labeled antibodies- both positive and 
negative- used among other factors.  Finally, alternative or larger clinical cohorts may 
find more significant relationships. However, given a moderately sized cohort, we believe 
our study was adequately powered to detect what we would interpret as clinical 
meaningful associations. 
 
4.6 Conclusion 
 The preliminary data of our research establishes a close relationship between 
PMP and platelet count, revealing that the two measures are most likely affected by the 
same underlying physiologic processes.  PMP concentration does correlate with the 
degree of sepsis severity and patient survival; however, platelet count provides a much 
more convenient parameter for critical care physicians in determining the severity of 
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sepsis and short-term prognosis.  Although PMPs may not represent a useful new 
parameter for sepsis diagnosis, the outcome of this research could establish the basis for 
further studies examining why these two measures parallel so closely despite the 
destruction of platelets observed in sepsis.  Analysis of the remaining patients enrolled in 
this study will be necessary to confirm the results established in this thesis.
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